| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8528ff66470c896b6da8ed059464e31f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c433784cd51658b73e136d04058bbf1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate |
2010-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93a94b4252674d5bb2e799a5791bc179
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b888f03e7cdc0ac56674d6bab84019d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26a774257dbc0a584c2d3b12e3646eb6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6508c832d36989a4dec5d1419d9de1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_563ab71ef807f206ed942511532639e3 |
| publicationDate |
2013-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20130079303-A |
| titleOfInvention |
Reactivity to Angiogenesis Inhibitors |
| abstract |
The present invention is characterized physiologically and pathologically by treatment with angiogenesis inhibitors such as bevacizumab to determine the presence of one or more heterologous alleles of the vascular endothelial growth factor receptor-1 (VEGFR-1) gene. The present invention relates to a method for improving the overall survival of patients suffering from angiogenesis-related or malignant diseases. The invention further relates to physiological and pathological processes by determining the presence of one or more heterologous alleles of the vascular endothelial growth factor receptor-1 (VEGFR-1) gene by treatment with angiogenesis inhibitors such as bevacizumab. It provides a way to improve progression-free survival of patients suffering from angiogenesis-related or malignant diseases. The invention also provides a method for assessing a patient's responsiveness to angiogenesis inhibitors by determining the presence of one or more heterologous alleles of the vascular endothelial growth factor receptor-1 (VEGFR-1) gene. |
| priorityDate |
2009-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |